Teriflunomide Concentrations in Cerebrospinal Fluid and Plasma in Patients with Multiple Sclerosis: A Pharmacokinetic Study

BACKGROUND: Teriflunomide is a disease modifying treatment (DMT) approved for relapsing-remitting multiple sclerosis (RRMS) in adults and children. It reduces lymphocyte proliferation by inhibiting the mitochondrial enzyme dihydroorotate dehydrogenase (DHODH) and thereby the pyrimidine synthesis. Al...

Descripción completa

Detalles Bibliográficos
Autores principales: Lycke, Jan, Farman, Helen, Nordin, Anna
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2023
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9911485/
https://www.ncbi.nlm.nih.gov/pubmed/36729276
http://dx.doi.org/10.1007/s40263-023-00985-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9911485/
https://www.ncbi.nlm.nih.gov/pubmed/36729276
http://dx.doi.org/10.1007/s40263-023-00985-x

Ejemplares similares